Cutaneous toxicities associated with vemurafenib therapy in 107 patients with<i>BRAF</i>V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations

Abstract

Vemurafenib appears to have a predictable and manageable AE profile. Proactive management can limit the impact of AEs on patients, allowing treatment to continue despite toxicities.